Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Shwachman-Bodian-Diamond syndrome (SBDS) protein is a direct inhibitor of protein phosphatase 2A (PP2A) activity and overexpressed in acute myeloid leukaemia.
Dun MD, Mannan A, Rigby CJ, Butler S, Toop HD, Beck D, Connerty P, Sillar J, Kahl RGS, Duchatel RJ, Germon Z, Faulkner S, Chi M, Skerrett-Byrne D, Murray HC, Flanagan H, Almazi JG, Hondermarck H, Nixon B, De Iuliis G, Chamberlain J, Alvaro F, de Bock CE, Morris JC, Enjeti AK, Verrills NM. Dun MD, et al. Among authors: enjeti ak. Leukemia. 2020 Dec;34(12):3393-3397. doi: 10.1038/s41375-020-0814-0. Epub 2020 Apr 8. Leukemia. 2020. PMID: 32269318 Free PMC article. No abstract available.
Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors.
Smith AM, Dun MD, Lee EM, Harrison C, Kahl R, Flanagan H, Panicker N, Mashkani B, Don AS, Morris J, Toop H, Lock RB, Powell JA, Thomas D, Guthridge MA, Moore A, Ashman LK, Skelding KA, Enjeti A, Verrills NM. Smith AM, et al. Oncotarget. 2016 Jul 26;7(30):47465-47478. doi: 10.18632/oncotarget.10167. Oncotarget. 2016. PMID: 27329844 Free PMC article.
Targeting Apoptotic Pathways in Acute Myeloid Leukaemia.
Sillar JR, Enjeti AK. Sillar JR, et al. Among authors: enjeti ak. Cancers (Basel). 2019 Oct 26;11(11):1660. doi: 10.3390/cancers11111660. Cancers (Basel). 2019. PMID: 31717784 Free PMC article. Review.
Prolonged administration of low-dose cytarabine and thioguanine in elderly patients with acute myeloid leukaemia (AML) achieves high complete remission rates and prolonged survival.
Arthur C, Jeffrey A, Yip E, Katsioulas V, Nalpantidis A, Kerridge I, Greenwood M, Coyle L, Mackinlay N, Fay K, Enjeti A, Shortt J, Stevenson W. Arthur C, et al. Leuk Lymphoma. 2020 Apr;61(4):831-839. doi: 10.1080/10428194.2019.1697876. Epub 2019 Dec 6. Leuk Lymphoma. 2020. PMID: 31809629
Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia.
Murray HC, Enjeti AK, Kahl RGS, Flanagan HM, Sillar J, Skerrett-Byrne DA, Al Mazi JG, Au GG, de Bock CE, Evans K, Smith ND, Anderson A, Nixon B, Lock RB, Larsen MR, Verrills NM, Dun MD. Murray HC, et al. Among authors: enjeti ak. Leukemia. 2021 Jun;35(6):1782-1787. doi: 10.1038/s41375-020-01050-y. Epub 2020 Oct 16. Leukemia. 2021. PMID: 33067575 Free PMC article. No abstract available.
Blockade of ROS production inhibits oncogenic signaling in acute myeloid leukemia and amplifies response to precision therapies.
Germon ZP, Sillar JR, Mannan A, Duchatel RJ, Staudt D, Murray HC, Findlay IJ, Jackson ER, McEwen HP, Douglas AM, McLachlan T, Schjenken JE, Skerrett-Byrne DA, Huang H, Melo-Braga MN, Plank MW, Alvaro F, Chamberlain J, De Iuliis G, Aitken RJ, Nixon B, Wei AH, Enjeti AK, Huang Y, Lock RB, Larsen MR, Lee H, Vaghjiani V, Cain JE, de Bock CE, Verrills NM, Dun MD. Germon ZP, et al. Among authors: enjeti ak. Sci Signal. 2023 Mar 28;16(778):eabp9586. doi: 10.1126/scisignal.abp9586. Epub 2023 Mar 28. Sci Signal. 2023. PMID: 36976863
77 results